Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (351-360 of 463) with videos related to

Pageof 47
Sort By:
Journal of Crohn'S & Colitis|December 22, 2010
IBD patients need in health quality of care ECCO consensusMargarita Elkjaer, Gabrielle Moser, Walter Reinisch, et al.
The New England Journal of Medicine|September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Geert D'Haens, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.
Therapeutic Advances in Gastroenterology|November 9, 2022
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control studySimon J Hong, Sumona Bhattacharya, Aiya Aboubakr, et al.
Gastroenterology|March 14, 2020
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before DiagnosisJoana Torres, Francesca Petralia, Takahiro Sato, et al.
Gut|December 16, 2021
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel diseaseJudith Wellens, Matthew Edmans, Uri Obolski, et al.
Gut|February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trialsJulian Panés, William J Sandborn, Stefan Schreiber, et al.
Journal of Crohn'S & Colitis|September 27, 2021
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger PatientsAmanda Ricciuto, Christopher A Lamb, Eric I Benchimol, et al.
Inflammatory Bowel Diseases|May 20, 2022
High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease CourseStephanie L Gold, Loren G Rabinowitz, Laura Manning, et al.
Pageof 47

Showing results (351-360 of 463) with videos related to

Sort By:
Pageof 47
Journal of Crohn'S & Colitis|December 22, 2010
IBD patients need in health quality of care ECCO consensusMargarita Elkjaer, Gabrielle Moser, Walter Reinisch, et al.
The New England Journal of Medicine|September 29, 2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Geert D'Haens, et al.
Gut|October 21, 2020
Effect of IBD medications on COVID-19 outcomes: results from an international registryRyan C Ungaro, Erica J Brenner, Richard B Gearry, et al.
The American Journal of Gastroenterology|January 8, 2025
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical TrialBruce E Sands, David T Rubin, Edward V Loftus, et al.
Therapeutic Advances in Gastroenterology|November 9, 2022
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control studySimon J Hong, Sumona Bhattacharya, Aiya Aboubakr, et al.
Gastroenterology|March 14, 2020
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before DiagnosisJoana Torres, Francesca Petralia, Takahiro Sato, et al.
Gut|December 16, 2021
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel diseaseJudith Wellens, Matthew Edmans, Uri Obolski, et al.
Gut|February 18, 2017
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trialsJulian Panés, William J Sandborn, Stefan Schreiber, et al.
Journal of Crohn'S & Colitis|September 27, 2021
Inflammatory Bowel Disease Clinical Activity is Associated with COVID-19 Severity Especially in Younger PatientsAmanda Ricciuto, Christopher A Lamb, Eric I Benchimol, et al.
Inflammatory Bowel Diseases|May 20, 2022
High Prevalence of Malnutrition and Micronutrient Deficiencies in Patients With Inflammatory Bowel Disease Early in Disease CourseStephanie L Gold, Loren G Rabinowitz, Laura Manning, et al.
Pageof 47